"We continue to make substantial progress recruiting patients into our Phase III HEAT trial for ThermoDox(R). We continue to track well against our goal to complete enrollment by the end of this year," said Michael Tardugno, President and CEO of Celsion. "We have exceeded our goal of opening enrollment at 70 clinical trial sites with 74 enrolling world-wide. The Phase I/II DIGNITY trial of ThermoDox(R) in patients with recurrent chest wall breast cancer (RCW) also continues to advance. We are currently enrolling patients in the 50mg/m2 dosing cohort, which will be used to determine our therapeutic dose."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.